Chemotherapy and Immunotherapy of Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 104
Special Issue Editors
Interests: supportive care in cancer; bone metastases; side effects of immune checkpoint inhibitors; multiple myeloma; advanced bladder cancer; metastatic kidney cancer; metastatic prostate cancer
Special Issues, Collections and Topics in MDPI journals
Interests: lung cancer; bone metastases; adverse events of targeted cancer therapies; immune-checkpoint inhibitor; malignant pleural effusion
Special Issue Information
Dear Colleagues,
Effective targeted therapies and immunotherapies, such as immune checkpoint inhibitors (ICIs), have led to a major paradigm shift in the therapy of lung cancer. Tremendous treatment effects led to the extensive use of ICIs in metastatic as well as limited disease. ICIs are applied as monotherapy or in combination with chemotherapy for definitive, neoadjuvant, and adjuvant treatments, or as consolidation therapy following chemoradiation. Due to a growing number of indication approvals, it can be expected that most lung cancer patients will receive immunotherapy at some point during their treatment.
Despite all these benefits, predicting who will respond to ICI therapy remains difficult due to the lack of distinct biomarkers. Some patients still present with primary refractory disease or progress after an initial response. Furthermore, immunotherapies introduced possible adverse events that were barely observed in traditional systemic cancer treatment.
It is thus important to explore and further evaluate additional targets and applications for immunotherapy in lung cancer. Furthermore, it is of utmost importance to define potential biomarkers for ICI response and explore intersections of the effectiveness of ICI in combination with chemotherapy.
Dr. Sonia Vallet
Dr. Klaus Hackner
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint inhibitors
- immunotherapy
- lung cancer
- programmed-death ligand
- chemoimmunotherapy
- non-small-cell lung cancer
- small-cell lung cancer
